CD44<sup>+</sup>/CD24<sup>−</sup>Cells Are Transit Progenitors and Do Not Determine the Molecular Subtypes and Clinical Parameters in Breast Carcinomas

Lu, Xinquan; Xu, Kejia; Lü, Huiyan; Yin, Yuhui; Ma, Chunyan; Li, Huixiang; Suo, Zhenhe

doi:10.3109/01913123.2010.544843

Cited by 16 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 8 – 10 However, other studies showed that CD24 is not a cancer stem cell marker. 11 , 12 , 14 For example, Xu et al 14 found that both A549 and H560 CD24 + cells did not show enhanced tumor-forming ability than CD24 − cells. In this study, using the soft agar assay, we demonstrated that the CD24 + subpopulation has self-renewal properties.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of CD24 as a marker for tumorigenesis of melanoma

Tang

Guo

Wang

et al. 2018

OTT

View full text Add to dashboard Cite

ObjectiveCutaneous melanoma (CM) is a common skin cancer. Surgery is still the primary treatment for CM, as melanoma is resistant to chemotherapy. In the recent years, it has been found that cancer stem-like cells (CSCs) are responsible for this drug resistance. CD24 is a widely used marker to isolate CSCs. In this study, we aimed to analyze the properties of CD24+ and CD24− subpopulation of melanoma cells.Materials and methodsWe isolated CD24+ cells CSCs using magnetic-activated cell sorting system. We extracted total RNA and carried out reverse transcription polymerase chain reaction analysis. We counted the cell colonies using soft agar assay and assessed the cell invasion using cell migration assay. We implanted CD24+ or CD24− cells into the flank of non-obese diabetic severe combined immunodeficiency mice, and measured the tumor volumes every 5 days until the end of the experiment. We carried out immunohistochemical analysis to study the tissue sections.ResultsWe demonstrated that the CD24+ subpopulation has self-renewal properties in vitro and in vivo by using soft agar assay and xenograft tumor model. Furthermore, we confirmed that CD24 expression is accompanied by activation of Notch1 signaling pathway.ConclusionThis study provides new knowledge on the role of CD24 in the tumorigenic ability of melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 10 However, other studies showed that lack of CD24 expression appears to be critical for the identification of the breast cancer stem-like cells (CSCs). 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

Identification of CD24 as a marker for tumorigenesis of melanoma

Tang

Guo

Wang

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…breast tumor progression or patient survival (13,14). Further studies demonstrated that the CD44 + /CD24 -/low cells were transit progenitors; however, they did not determine either the molecular subtype or clinical parameters in breast cancer (15).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

et al. 2016

View full text Add to dashboard Cite

Abstract.A subpopulation of breast cancer cells with cluster of differentiation (CD)44-positive and CD24-negative expression has been reported to have stem cell properties and to have a higher tumorigenic capacity than other cells. However, the clinico pathological characteristics of this subpopulation are not fully understood. In this study, we aimed to identify the correlations between the expression of CD44 and CD24 and clinicopathological parameters and overall survival. We studied specimens from 262 patients with invasive breast cancer. Immunohistochemical staining for CD44 and CD24 was performed using tissue microarrays. The clinico pathological factors were evaluated from the patients' medical records. In correlation analysis, CD44 expression was significantly associated with human epidermal growth factor receptor 2 (HER2)-negative status (P<0.001). Conversely, CD24 expression was significantly associated with HER2-positive status (P<0.001). CD44 and CD24 expression did not demonstrate any correlation with the age, tumor size, axillary lymph node metastasis status, tumor stage, histological grade, estrogen receptor status and progesterone receptor status of patients. Upon survival analysis, there was no statistical difference in overall survival according to the expression of CD44 and CD24. The results from this study suggest that CD44 and CD24 are clinically significant markers associated with breast tumorigenesis, but not sufficient factors in determining the prognosis of invasive breast cancer.

show abstract

“…Generally speaking, CD44 is indicated to be a promising biomarker for diagnosis 92 and prognosis. 93 , 94 …”

Section: Clinical Significance Of Cd44mentioning

confidence: 99%

The role of CD44 in epithelial–mesenchymal transition and cancer development

Tian

Yuan

et al. 2015

OTT

151

110

View full text Add to dashboard Cite

CD44, a multi-structural and multifunctional transmembrane glycoprotein, was initially identified as a receptor for hyaluronan that participates in both physiological and pathological processes. CD44 is found to be closely linked to the development of various solid tumors. Molecular studies have revealed that high CD44 expression was correlated with the phenotypes of cancer stem cells and epithelial–mesenchymal transition, thereby contributing to tumor invasion, metastasis, recurrence, and chemoresistance. Correspondingly, blockade of CD44 has been demonstrated to be capable of attenuating the malignant phenotype, slowing cancer progression, and reversing therapy resistance. Clinical analyses showed that high CD44 expression is associated with poor survival of various cancer patients, indicating that CD44 can be a potential prognostic marker. In this review, we summarize recent research progress of CD44 on tumor biology and the clinical significance of CD44.

show abstract

CD44⁺/CD24⁻Cells Are Transit Progenitors and Do Not Determine the Molecular Subtypes and Clinical Parameters in Breast Carcinomas

Cited by 16 publications

References 23 publications

Identification of CD24 as a marker for tumorigenesis of melanoma

Identification of CD24 as a marker for tumorigenesis of melanoma

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

The role of CD44 in epithelial–mesenchymal transition and cancer development

Contact Info

Product

Resources

About

CD44+/CD24−Cells Are Transit Progenitors and Do Not Determine the Molecular Subtypes and Clinical Parameters in Breast Carcinomas

Cited by 16 publications

References 23 publications

Identification of CD24 as a marker for tumorigenesis of melanoma

Identification of CD24 as a marker for tumorigenesis of melanoma

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

The role of CD44 in epithelial&ndash;mesenchymal transition and cancer development

Contact Info

Product

Resources

About

CD44⁺/CD24⁻Cells Are Transit Progenitors and Do Not Determine the Molecular Subtypes and Clinical Parameters in Breast Carcinomas

The role of CD44 in epithelial–mesenchymal transition and cancer development